Browse PR assessments Search PR models Search Reset
Showing 15 of 15 models
15 models 13 legacy PR · 2 V4 assessments
Legacy versions: V1 5 · V2 6 · V3 2
Legacy PR rows are read at build time from release_package/database/cellmodeldb.sqlite; the website does not recalculate scores.
No models match this search. Try a model name, Entity ID, organ, target, or PR version.
Colon/Intestine · 1
Target reference enterocytes · GENERAL_EPITHELIAL_CONTEXT
Spearman rho 0.707474
Rank / percentile 23/154 / 85.621%
Delta rho -0.0680778268
NES NOT_DEFINED
Gene-set size 921
Caveat Tumour-control role retained; PR does not change database role.
Status FORMAL Kidney · 2 Entity_ID: KIDNEY-ENT-002
V1
Target reference proximal tubule cells · proximal tubular epithelial
Spearman rho 0.558464
Rank / percentile 136/154 / 11.765%
Delta rho -0.2102363253
NES NOT_DEFINED
Gene-set size 919
Status FORMAL Entity_ID: KIDNEY-ENT-001
V3
Target reference proximal tubule cells · proximal tubular epithelial
Spearman rho 0.513163
Rank / percentile 144/154 / 6.536%
Delta rho NOT_DEFINED
NES NOT_DEFINED_BY_V3_NULL_SIGN
Gene-set size 919
Status FORMAL Liver · 1 Entity_ID: LIV-ENT-A03-009
V2
Target reference hepatic stellate cells · HEPATIC_STELLATE
Spearman rho 0.495528
Rank / percentile 77/154 / 50.327%
Delta rho -0.1194289265
NES NOT_DEFINED
Gene-set size 365
Status FORMAL Lung · 5
Target reference respiratory basal cells · PROPAGATED_MODEL
Spearman rho 0.734071
Rank / percentile 16/154 / 90.196%
Delta rho -0.0648966577
NES NOT_DEFINED
Gene-set size 147
Status FORMAL
Target reference alveolar cells type 2 · TUMOUR_DERIVED_LINE
Spearman rho 0.728273
Rank / percentile 11/154 / 93.464%
Delta rho -0.0331284011
NES NOT_DEFINED
Gene-set size 295
Caveat Tumour-control role retained; PR does not change database role.
Status FORMAL
Target reference respiratory basal cells · PROPAGATED_MODEL
Spearman rho 0.575980
Rank / percentile 47/154 / 69.935%
Delta rho -0.0783202076
NES NOT_DEFINED
Gene-set size NOT_DEFINED
Status FORMAL
Target reference fibroblasts / PRTGT-005; accepted proxy with limitation
Assessment V4 Formal Assessment
Replicate evidence 3 replicate results
Caveat Replicate-level assessment; no single model-level score is aggregated.
Target reference fibroblasts / PRTGT-005; accepted proxy with limitation
Assessment V4 Formal Assessment
Replicate evidence 3 replicate results
Caveat Replicate-level assessment; no single model-level score is aggregated. Ovary · 1
Target reference granulosa cells · Granulosa cell
Spearman rho 0.659390
Rank / percentile 30/154 / 81.046%
Delta rho NOT_DEFINED
NES 1.095648
Gene-set size 218
Caveat Granulosa proxy caveat retained from the frozen V3 target mapping.
Status FORMAL Skeletal Muscle · 1
Target reference myosatellite cells · Human myoblast-derived differentiated myotube system
Spearman rho 0.691259
Rank / percentile 40/154 / 74.510%
Delta rho -0.0538316890
NES NOT_DEFINED
Gene-set size 241
Status FORMAL Skin · 1
Target reference basal keratinocytes · skin/epidermis keratinocyte
Spearman rho 0.766670
Rank / percentile 3/154 / 98.693%
Delta rho -0.0342592142
NES NOT_DEFINED
Gene-set size 289
Status FORMAL Vascular · 3
Target reference vascular endothelial cells · TIME
Spearman rho 0.738020
Rank / percentile 1/154 / 100.000%
Delta rho 0.0000000000
NES NOT_DEFINED
Gene-set size 454
Status FORMAL
Target reference vascular endothelial cells · HMEC-1
Spearman rho 0.750336
Rank / percentile 7/154 / 95.556%
Delta rho -0.0141165373
NES NOT_DEFINED
Gene-set size 454
Status FORMAL
Target reference vascular endothelial cells · hCMEC/D3
Spearman rho 0.720691
Rank / percentile 17/154 / 89.542%
Delta rho -0.0246914376
NES NOT_DEFINED
Gene-set size NOT_DEFINED
Status FORMAL PR status semantics
FORMAL Frozen reportable PR result in the approved public release.
HOLD Retained governance status; not zero, failed, or low PR.
EXPLORATORY Contextual or pilot evidence, not included in the formal count.
NOT_ASSESSED No formal PR assessment is available in PUBLIC_RC1; this is not a low-relevance conclusion. Disease Fidelity addresses stimulus-response similarity to patient disease. The current HaCaT psoriasis pilot is not a validated Disease Fidelity result.